Hrt Financial LP Ultragenyx Pharmaceutical Inc. Transaction History

Hrt Financial LP

$18.1 Billion
Q3 2024

A detailed history of Hrt Financial LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Hrt Financial LP holds 23,675 shares of RARE stock, worth $996,007. This represents 0.01% of its overall portfolio holdings.

Number of Shares

23,675

Holding current value

$996,007

% of portfolio

0.01%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$40.21 - $59.36 $951,971 - $1.41 Million	23,675 New	23,675 $1.32 Million
Q1 2024 May 13, 2024	SELL	$43.02 - $53.69 $448,698 - $559,986	-10,430 Reduced 57.0%	7,869 $367,000
Q4 2023 Feb 09, 2024	BUY	$31.73 - $49.19 $580,627 - $900,127	18,299 New	18,299 $875,000
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $1.82 Million - $2.55 Million	48,838 Added 466.81%	59,300 $2.74 Million
Q1 2023 May 12, 2023	SELL	$36.99 - $48.71 $740,613 - $975,271	-20,022 Reduced 65.68%	10,462 $419,000
Q4 2022 Feb 10, 2023	BUY	$33.72 - $46.33 $1.03 Million - $1.41 Million	30,484 New	30,484 $1.41 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $12.2 Million - $16.1 Million	-156,948 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $14.5 Million - $18.2 Million	156,948 New	156,948 $15 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.6M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$418 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$236 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$215 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$175 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$129 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.95B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account